查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867242

良性前列腺增生治療市場依藥物類別、學名藥狀態、通路及劑型分類－2025年至2032年全球預測

Benign Prostatic Hypertrophy Drugs Market by Drug Class, Generic Status, Distribution Channel, Dosage Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

良性前列腺增生治療市場預計到 2032 年將成長至 95.9 億美元，複合年成長率為 7.18%。

關鍵市場統計數據
基準年 2024 55億美元
預計年份：2025年 58.9億美元
預測年份 2032 95.9億美元
複合年成長率 (%) 7.18%

權威深入分析了影響良性前列腺增生藥物治療方法和獲取趨勢的臨床、監管和商業性因素。

本執行摘要探討了良性前列腺增生藥物治療領域複雜的臨床、監管和商業性環境，特別關注人口老化、臨床指南不斷更新以及供應鏈現狀變化等因素交織的影響。治療環境面臨藥物安全性審查日益嚴格、現有藥物專利專利到期以及對兼顧療效和耐受性的聯合治療日益成長的需求等挑戰。說明將整合活性成分組合、處方實踐和分銷模式的最新進展，為評估政策、投資和研發決策的相關人員提供一個連貫的觀點。

簡要回顧良性前列腺增生治療領域中正在重新定義治療策略、治療途徑和競爭動態的關鍵臨床、商業性和監管轉折點

良性前列腺增生（BPH）的治療格局正在經歷一場變革，這反映了醫療保健、藥物研發和患者參與等方面的更廣泛變化。關鍵的轉變包括從單一療法轉向聯合療法，以尋求在症狀控制和延緩疾病進展方面產生協同效應。同時，植物療法的實證基礎日益成熟，真實世界數據（RWE）也擴大被納入療效比較評估中，從而拓展了治療選擇並影響了處方行為。

評估2025年關稅對良性前列腺增生治療藥物的購買、生產韌性和商業性準備的影響

2025年實施的關稅及相關貿易政策措施，給藥品供應鏈帶來了日益複雜的局面，並對生產決策、籌資策略和庫存管理產生了連鎖反應。關稅有可能增加進口原料藥和成品藥的到岸成本，迫使生產商重新評估採購方案、最佳化生產佈局並重新談判供應商合約。在價格和報銷受到嚴格監管的地區，這些額外的成本壓力可能會擠壓利潤空間，促使企業提高效率，並加快生產在地化進程，以降低外部貿易摩擦的風險。

將藥物分類、學名藥狀態、通路和劑型特徵與處方行為、獲取途徑和產品策略聯繫起來的詳細細分分析

治療領域細分揭示了臨床和商業性動態的差異，這對於貫穿研發、商業化和分銷的策略規劃至關重要。依藥物類別分類，產品組合涵蓋5α-還原酶抑制劑、α阻斷劑、聯合治療和植物療法。 5α-還原酶抑制劑類別的特徵是具有不同的活性分子，例如度他雄胺和非那雄胺，每種分子都具有不同的藥物動力學特性和現有的臨床數據，這些都會影響處方醫生的選擇。 α受體阻斷劑涵蓋多種藥物，包括阿夫唑嗪、多沙唑嗪、西洛多辛、Tamsulosin和特拉唑嗪，選擇性譜和不利事件決定了特定患者表現型的治療選擇。聯合治療方案包括5α-還原酶抑制劑與選擇性α阻斷劑的合併用藥；常見的合併用藥包括度他雄胺+Tamsulosin和非那雄胺+Tamsulosin。這些組合療法旨在既能即時緩解症狀，又能長期縮小攝護腺體積。植物療法，例如BETA-谷甾醇、非洲臀果木和鋸棕櫚，仍然是尋求輔助或替代療法的患者以及將患者意願納入共同決策的臨床醫生可行的選擇。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在良性前列腺增生症的治療中，新型BETA3促效劑療法因其能促進膀胱平滑肌鬆弛而得到更廣泛的應用。
  • 擴展一個整合遠端監測和患者報告結果的數位健康平台，用於良性前列腺增生症治療評估。
  • 前列腺動脈栓塞術作為一種微創手術，逐漸成為傳統良性前列腺增生（BPH）手術的替代方案。
  • 開發一種聯合治療通訊協定，利用5α-還原酶抑制劑和植物化學萃取物來增強前列腺體積縮小效果。
  • 越來越重視生物標記和基因譜分析，以實現良性前列腺增生症藥物治療方案的個人化。
  • 評估選擇性雄性激素調變器以緩解良性前列腺增生症狀和減少性副作用的臨床試驗激增

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 良性攝護腺增生藥物市場（依藥物類別分類）

  • 5α-還原酶抑制劑
    • 度他雄胺
    • 非那雄胺
  • α受體阻斷劑
    • 阿夫唑嗪
    • 多沙唑嗪
    • 西洛多辛
    • Tamsulosin
    • 特拉唑嗪
  • 聯合治療
    • 度他雄胺+Tamsulosin
    • 非那雄胺+Tamsulosin
  • 植物療法
    • BETA-谷甾醇
    • 非洲臀果木
    • 鋸棕櫚

第9章 良性攝護腺增生治療市場（依學名藥類別分類）

  • 品牌產品
    • 阿伏達特
    • 弗洛馬克斯
    • 賈林
    • 保列治
  • 非專利的

第10章 良性攝護腺增生治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 良性攝護腺增生治療市場（依劑型分類）

  • 膠囊
    • 緩釋性
    • 快速起效配方
  • 口服液
  • 藥片
    • 緩釋性
    • 快速起效配方

第12章 良性攝護腺增生治療市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 良性攝護腺增生治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國良性攝護腺增生治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Viatris Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Cipla Limited
    • Lupin Limited
Product Code: MRR-CB04E056547E

The Benign Prostatic Hypertrophy Drugs Market is projected to grow by USD 9.59 billion at a CAGR of 7.18% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.50 billion
Estimated Year [2025] USD 5.89 billion
Forecast Year [2032] USD 9.59 billion
CAGR (%) 7.18%

An authoritative orientation to the clinical, regulatory, and commercial factors reshaping therapeutic approaches and access dynamics for benign prostatic hypertrophy drugs

This executive summary introduces the complex clinical, regulatory, and commercial environment surrounding pharmacologic management of benign prostatic hypertrophy, emphasizing the confluence of aging demographics, evolving clinical guidelines, and shifting supply chain realities. It situates the therapeutic landscape within an era of intensified scrutiny over drug safety profiles, patent expirations for legacy agents, and rising interest in combination regimens that aim to balance efficacy with tolerability. The narrative that follows synthesizes recent developments in active ingredient portfolios, prescribing practices, and distribution modalities to provide a cohesive perspective for stakeholders evaluating policy, investment, or R&D decisions.

The introduction recognizes the heterogeneity of patient journeys-from initial symptom management to advanced intervention-and underscores how therapeutic choice is increasingly influenced by comorbidity management, polypharmacy concerns, and patient preferences for convenience and quality of life. Clinical guidelines continue to refine criteria for intervention, while payers and providers reassess treatment pathways to optimize outcomes and cost-effectiveness. In parallel, innovation is concentrated on improving adherence through formulation science and on identifying complementary therapies that mitigate adverse effects of standard agents. This section frames the subsequent analysis by highlighting the principal forces that are likely to drive strategic priorities across industry, clinical practice, and regulatory spheres.

A concise exploration of the pivotal clinical, commercial, and regulatory transitions that are redefining therapeutic strategies, access, and competitive dynamics for BPH treatments

The landscape for benign prostatic hypertrophy therapeutics has undergone transformative shifts that reflect broader changes across healthcare delivery, drug development, and patient engagement. Key shifts include a move from single-agent paradigms toward combination strategies that seek synergistic gains in symptom control and disease progression mitigation. This is complemented by a parallel maturation of evidence around phytotherapeutic options and the integration of real-world evidence into comparative effectiveness assessments, which together broaden therapeutic choice and influence prescribing behavior.

Another transformative element is the rapid digitization of the patient journey, which has altered how prescriptions are accessed, refilled, and monitored. Telehealth consultations and digital adherence tools are increasingly common, prompting manufacturers and distributors to re-evaluate channels for patient support programs and post-marketing surveillance. Regulatory environments have also evolved, with authorities emphasizing pharmacovigilance and clearer benefit-risk communication, particularly for agents with long-term exposure in older populations. In addition, intellectual property transitions and the rise of high-quality generics are intensifying competition and prompting lifecycle strategies focused on formulation improvements, combination approvals, and line extensions. Collectively, these shifts compel manufacturers, payers, and clinicians to reassess clinical value propositions and to prioritize interventions that demonstrably improve long-term patient outcomes while maintaining affordability and access.

An assessment of how 2025 tariff measures influenced pharmaceutical sourcing, manufacturing resilience, and commercial readiness for benign prostatic hypertrophy therapeutics

The imposition of tariffs and related trade policy measures in 2025 introduced incremental complexity into the supply chain for pharmaceuticals, with cascading effects on manufacturing decisions, procurement strategies, and inventory management. Tariffs can increase landed costs for imported active pharmaceutical ingredients and finished dosage forms, prompting manufacturers to review sourcing options, re-optimize production footprints, and renegotiate supplier contracts. In jurisdictions where pricing and reimbursement are tightly regulated, these added cost pressures can compress margins, catalyze efficiency drives, and accelerate efforts to localize manufacturing to reduce exposure to external trade friction.

Beyond direct cost implications, tariffs have also influenced the cadence of regulatory submissions and contract negotiations. Procurement officers and health systems have increasingly factored geopolitical risk into multi-year supplier agreements and contingency planning, driving a preference for diversified supplier networks and buffer inventories. For manufacturers, the response has included greater emphasis on supply chain resilience through dual sourcing, strategic stockpiling of critical intermediates, and investment in regional production capabilities. Importantly, these adaptations affect more than cost lines; they shape product availability, launch sequencing for new formulations or combination therapies, and the competitive landscape as some firms are better positioned to absorb or mitigate tariff-related disruptions. In sum, tariff dynamics in 2025 acted as an accelerant for strategic realignment across sourcing, manufacturing, and commercialization decisions within the therapeutic area.

In-depth segmentation narrative linking drug classes, generic status, distribution channels, and dosage form attributes to prescribing behavior, access pathways, and product strategies

Segmentation of the therapeutic domain reveals differentiated clinical and commercial dynamics that are essential for strategic planning across development, commercialization, and distribution. Based on drug class, the portfolio spans 5-alpha reductase inhibitors, alpha blockers, combination therapy, and phytotherapy. The 5-alpha reductase inhibitors category is characterized by distinct active molecules such as dutasteride and finasteride, each with divergent pharmacokinetic properties and legacy clinical data that influence prescriber choice. Alpha blockers encompass a spectrum of agents including alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, where selectivity profiles and adverse event considerations drive therapeutic selection for specific patient phenotypes. Combination therapy options pair a 5-alpha reductase inhibitor with a selective alpha blocker, with commonly observed pairings involving dutasteride plus tamsulosin and finasteride plus tamsulosin; these combinations are positioned to address both immediate symptom relief and longer-term prostate volume reduction. Phytotherapeutic alternatives-such as beta-sitosterol, pygeum, and saw palmetto-remain relevant for patients seeking complementary or alternative approaches and for clinicians who integrate patient preference into shared decision-making.

Based on generic status, the landscape comprises both branded and generic offerings, with branded agents including noted trade names that have historically shaped prescribing habits and promotional approaches. Patent expirations and the ensuing generic entries have prompted lifecycle management strategies among originators, including reformulation, indication consolidation, and patient support initiatives. Based on distribution channel, treatment access is mediated through hospital pharmacies, online pharmacies, and retail pharmacies; each channel has its own dynamics around procurement cycles, patient counseling opportunities, and reimbursement interactions. Based on dosage form, therapeutic presentations include capsules, oral solutions, and tablets, with formulations differentiated by release profile-capsules and tablets are available in extended release and immediate release variants-affecting adherence, dosing convenience, and tolerability profiles. Recognizing these segmentation nuances is critical for aligning product development, commercial messaging, and distribution strategies with clinician needs and patient expectations.

A regional synthesis highlighting how regulatory diversity, reimbursement frameworks, and healthcare infrastructure drive distinct access and adoption patterns across global territories

Regional differences materially shape how therapies are developed, approved, reimbursed, and ultimately accessed by patients, with each geographic area presenting distinct regulatory, payer, and clinical practice realities. In the Americas, healthcare systems vary from publicly funded national programs to predominantly private insurance frameworks, influencing formulary negotiation approaches, tendering practices, and the adoption timeline for combination therapies and novel formulations. Reimbursement mechanisms and clinical guideline endorsements interact to determine how quickly new evidence is translated into changes in standard practice.

In Europe, the Middle East & Africa region, a mosaic of regulatory regimes and reimbursement environments requires tailored market access strategies that account for divergent price controls, varying levels of pharmacovigilance infrastructure, and differing capacities for local manufacturing. This complexity often necessitates regionalized clinical evidence generation and adaptive commercial models that reflect the heterogeneity of payer expectations. In the Asia-Pacific region, high population growth, increasing healthcare investment, and accelerating digital health adoption are creating fertile conditions for expanded access models, greater emphasis on cost-effective generics, and the rapid scaling of e-prescription and online pharmacy channels. Across all regions, local clinical guidelines, demographic trends, and supply chain capabilities are primary determinants of product uptake and long-term positioning.

An analytical overview of competitive approaches and strategic maneuvers by incumbent and emerging companies shaping product differentiation and market positioning

Competitive dynamics in this therapeutic area reflect a mix of established pharmaceutical firms with legacy branded assets and agile generic manufacturers and specialty companies pursuing niche positioning. Incumbent originator companies continue to leverage clinical legacy, physician relationships, and brand recognition, while generics manufacturers focus on cost competitiveness, reliable supply, and partnerships with distributors and procurement consortia. Innovation is observable in areas such as fixed-dose combination approvals, reformulated extended-release products, and patient support services designed to improve adherence and persistence.

Strategic collaborations and licensing arrangements are increasingly prominent as a way to accelerate geographic expansion and to share risk related to manufacturing localization or regulatory submissions. Companies that invest in clinical evidence demonstrating improved outcomes with combination regimens or novel formulations tend to achieve stronger clinician buy-in. At the same time, those that can integrate digital support tools, curated educational content for prescribers, and real-world data capture into their go-to-market strategies create differentiated value propositions that extend beyond price-focused competition. The interplay between brand stewardship and cost-effective manufacturing capability will remain central to competitive performance in the near term.

A set of practical, high-impact strategic moves for manufacturers, payers, and distributors to strengthen resilience, clinical value, and uptake of BPH treatment options

Industry leaders should prioritize a portfolio of actions designed to enhance resilience, clinical relevance, and commercial differentiation. First, aligning clinical development and post-marketing evidence generation with real-world effectiveness and safety endpoints will strengthen value narratives with payers and prescribers. Demonstrating tangible benefits of combination regimens or new formulations in routine care settings will facilitate guideline incorporation and payer acceptance. Second, optimizing supply chain architecture to reduce exposure to single-source dependencies and trade-related shocks will protect product availability; strategies include regional manufacturing partnerships, dual sourcing of key intermediates, and collaborative inventory management with major distributors.

Third, investment in digital patient engagement and adherence technologies should be treated as a core component of product launch and lifecycle programs rather than an adjunct activity, because these tools can materially improve persistence and support outcome-based contracting. Fourth, tailored access strategies that reflect regional regulatory and reimbursement realities-ranging from evidence packages for health technology assessment committees to flexible pricing arrangements-will be essential to unlocking adoption across diverse jurisdictions. Finally, companies should explore targeted alliances with clinical centers and professional societies to co-create educational initiatives that address appropriate patient selection and long-term management, thereby elevating both clinical practice and product uptake.

A transparent methodological synopsis describing qualitative and secondary research integration, data validation approaches, and limitations to support reproducibility and strategic interpretation

The analysis underpinning this report synthesizes multiple research approaches to ensure robust, actionable insights. Primary research elements included structured interviews with clinical experts, formulary decision-makers, procurement leads, and specialty pharmacists to capture contemporary practice patterns and payer expectations. These qualitative inputs were complemented by targeted interviews with manufacturing and supply chain executives to understand sourcing strategies and capacity considerations. Secondary research incorporated regulatory documents, clinical trial registries, and peer-reviewed clinical literature to triangulate efficacy, safety, and guideline trends.

Data integrity was maintained through cross-validation of stakeholder claims against publicly available regulatory communications and clinical evidence. The methodology emphasized transparency in assumptions and documented limitations, including recognition of geographic variability in data availability. Where applicable, synthesis prioritized recent peer-reviewed findings and government-issued guidance to reflect current standards of care and regulatory priorities. Throughout the research process, ethical considerations guided outreach and data handling, and methodological choices were designed to support reproducibility and relevance to strategic decision-making.

A conclusive synthesis that distills implications for stakeholders and outlines the strategic levers necessary to convert emerging trends into sustainable clinical and commercial advantages

In conclusion, the therapeutic landscape for benign prostatic hypertrophy is being reshaped by convergent forces: clinical preferences shifting toward combination strategies, regulatory emphasis on safety and long-term outcomes, and commercial pressures arising from intellectual property transitions and supply chain volatility. These dynamics create both challenges and opportunities for stakeholders seeking to advance patient care while maintaining sustainable commercial models. Resilience in manufacturing and supply, strategic evidence generation, and patient-centric engagement will be the differentiators that determine which products and companies achieve durable success.

Looking ahead, organizations that proactively adapt to regional regulatory nuances, integrate digital adherence solutions, and align clinical development with real-world outcomes will be best positioned to influence standards of care and secure durable partnerships with payers and healthcare systems. Cross-functional collaboration-linking R&D, regulatory affairs, supply chain, and commercial teams-will be essential to translate insight into execution and to ensure that innovations meaningfully improve patient experiences and clinical endpoints.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of novel B3 agonist therapies targeting bladder smooth muscle relaxation in BPH management
  • 5.2. Expansion of digital health platforms integrating telemonitoring and patient reported outcomes in BPH therapy assessment
  • 5.3. Emergence of prostate arterial embolization as a minimally invasive alternative to traditional BPH surgical procedures
  • 5.4. Development of combination therapy protocols involving 5a reductase inhibitors with phytochemical extracts for enhanced prostate volume reduction
  • 5.5. Increasing focus on biomarkers and genetic profiling to personalize benign prostatic hyperplasia pharmacotherapy approaches
  • 5.6. Surge in clinical trials evaluating selective androgen receptor modulators to mitigate BPH symptoms with fewer sexual side effects

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Benign Prostatic Hypertrophy Drugs Market, by Drug Class

  • 8.1. 5-Alpha Reductase Inhibitors
    • 8.1.1. Dutasteride
    • 8.1.2. Finasteride
  • 8.2. Alpha Blockers
    • 8.2.1. Alfuzosin
    • 8.2.2. Doxazosin
    • 8.2.3. Silodosin
    • 8.2.4. Tamsulosin
    • 8.2.5. Terazosin
  • 8.3. Combination Therapy
    • 8.3.1. Dutasteride + Tamsulosin
    • 8.3.2. Finasteride + Tamsulosin
  • 8.4. Phytotherapy
    • 8.4.1. Beta-Sitosterol
    • 8.4.2. Pygeum
    • 8.4.3. Saw Palmetto

9. Benign Prostatic Hypertrophy Drugs Market, by Generic Status

  • 9.1. Branded
    • 9.1.1. Avodart
    • 9.1.2. Flomax
    • 9.1.3. Jalyn
    • 9.1.4. Proscar
  • 9.2. Generic

10. Benign Prostatic Hypertrophy Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Benign Prostatic Hypertrophy Drugs Market, by Dosage Form

  • 11.1. Capsule
    • 11.1.1. Extended Release
    • 11.1.2. Immediate Release
  • 11.2. Oral Solution
  • 11.3. Tablet
    • 11.3.1. Extended Release
    • 11.3.2. Immediate Release

12. Benign Prostatic Hypertrophy Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Benign Prostatic Hypertrophy Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Benign Prostatic Hypertrophy Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Merck & Co., Inc.
    • 15.3.2. GlaxoSmithKline plc
    • 15.3.3. Teva Pharmaceutical Industries Ltd.
    • 15.3.4. Novartis AG
    • 15.3.5. Boehringer Ingelheim International GmbH
    • 15.3.6. Viatris Inc.
    • 15.3.7. Sun Pharmaceutical Industries Ltd.
    • 15.3.8. Dr. Reddy's Laboratories Ltd.
    • 15.3.9. Cipla Limited
    • 15.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, B